SAN DIEGO, Feb. 9 /PRNewswire-FirstCall/ -- Sequenom, Inc. , a leading provider of fine mapping genotyping, methylation and gene expression analysis solutions, today announced that Sequenom President and Chief Executive Officer Harry Stylli, Ph.D. will present at the BIO CEO & Investor Conference 2007 on Wednesday, February 14 at 3:00 p.m. Eastern Time (12:00 noon Pacific time). The conference is being held at the Waldorf-Astoria Hotel in New York City.
(Logo: http://www.newscom.com/cgi-bin/prnh/20040415/SQNMLOGO)
Interested parties can access a live audio webcast and slide presentation at http://www.sequenom.com. An archived presentation will be available on the Web site for 14 days.
About Sequenom
Sequenom is committed to providing the best genetic analysis products that translate genomic science into superior solutions for biomedical research, agricultural applications, molecular medicine, and non-invasive prenatal testing. The Company’s proprietary MassARRAY(R) system is a high-performance nucleic acid analysis platform that efficiently and precisely measures the amount of genetic target material and variations therein. The system is able to deliver reliable and specific data from complex biological samples and from genetic target material that is only available in trace amounts. The Company has exclusively licensed intellectual property rights for the development and commercialization of non-invasive prenatal genetic tests for use with the MassARRAY system and other platforms.
Sequenom(R) and MassARRAY(R) are trademarks of SEQUENOM, Inc.
Photo: http://www.newscom.com/cgi-bin/prnh/20040415/SQNMLOGOAP Archive: http://photoarchive.ap.orgPRN Photo Desk: photodesk@prnewswire.comSequenom, Inc.
CONTACT: Company, John Sharp, Principal Financial Officer of Sequenom,Inc., +1-858-202-9032; or Investor Relations, Zachary Bryant,zbryant@lhai.com, or Jody Cain, jcain@lhai.com, both of Lippert, Heilshorn& Associates, +1-310-691-7100, for Sequenom, Inc.
Web site: http://www.sequenom.com//
